ADAM10 Prodomain Mutations Cause Late-Onset Alzheimer’s Disease: Not Just the Latest FAD  by Vassar, Robert
Neuron
PreviewsADAM10 Prodomain Mutations Cause Late-Onset
Alzheimer’s Disease: Not Just the Latest FADRobert Vassar1,*
1Department of Cell andMolecular Biology, The Feinberg School of Medicine, Northwestern University, 300 East Superior Street, Tarry 8-713,
Chicago, IL 60611-3006, USA
*Correspondence: r-vassar@northwestern.edu
http://dx.doi.org/10.1016/j.neuron.2013.09.031
In this issue of Neuron, Suh et al. (2013) describe two rare ADAM10 prodomain mutations that cause late-
onset Alzheimer’s disease by impairing prodomain chaperone function, attenuating a-secretase activity,
and reducing adult hippocampal neurogenesis. These results support both ADAM10 as a therapeutic target
and the amyloid hypothesis of Alzheimer’s disease.Alzheimer’s disease (AD) is characterized
by the cerebral accumulation of b-amyloid
(Ab), 38–43 amino acid peptides that self-
aggregate into fibrils that comprise hall-
mark AD lesions called amyloid plaques.
Evidence abounds that Ab accumulation
is a critical early AD event that starts a
pathogenic cascade ultimately leading
to synaptic loss, neuronal death, and
dementia (Hardy and Selkoe, 2002).
Biochemical, cellular, and animal-model
studies suggest that Ab is neurotoxic
and disrupts neuronal function at multiple
levels. Perhaps the most compelling evi-
dence implicating Ab in the etiology of
AD comes from human genetic studies
linking fully penetrant autosomal-domi-
nant mutations in amyloid beta (A4)
precursor protein (APP), presenilin 1
(PSEN1), and presenilin 2 (PSEN2) to
the occurrence of early-onset familial AD
(EO-FAD) (Tanzi, 2012). These rare ge-
netic cases of the disorder are very
aggressive, resulting in AD that typically
begins before the age of 60 years. In
contrast, late-onset AD (LOAD), the most
common form of the disease, appears
after 60 years of age. The genetic lesions
that cause EO-FAD total well over 200 in
number and are mostly missense muta-
tions in APP, PS1, and PS2. Without
exception, these EO-FAD mutations
either increase the ratio of the 42 amino
acid Ab isoform (Ab42) to the 40 amino
acid isoform (Ab40) or increase the pro-
duction of all lengths of Ab (total Ab).
APP duplication in trisomy 21 (Down syn-
drome) or rare duplications limited to
small chromosomal regions that include
the APP locus also cause EO-FAD by
raising total Ab production via increased250 Neuron 80, October 16, 2013 ª2013 ElseAPP dosage. Importantly, a novel
missense mutation that protects against
AD by reducing total Ab generation was
recently discovered in APP (Jonsson
et al., 2012), thus underscoring the critical
role of Ab in the pathophysiology of AD.
Together, the human genetic evidence
strongly suggests that Ab is centrally
involved in the etiology of EO-FAD. How-
ever, a definitive role for Ab in the patho-
genesis of LOAD has been controversial.
Although the major genetic risk factor for
LOAD, the apolipoprotein E ε4 variant
(ApoE4), is associated with increased
accumulation of cerebral Ab, the mecha-
nism by which ApoE4 causes increased
amyloid is not fully understood (Holtzman
et al., 2012). In addition, in the brain,
ApoE4 may exert Ab-independent effects
that contribute to AD pathogenesis and
cognitive decline. Thus, it has been
argued that although Ab accumulation
may cause EO-FAD, its role in LOAD has
not yet been firmly established.
Ab is generated by the sequential
proteolytic processing of APP via the
action of two aspartic proteases, the
b-secretase and g-secretase enzymes
(De Strooper et al., 2010). b-secretase,
also called b-site APP-cleaving enzyme
1 (BACE1), cleaves APP first to generate
the N terminus of Ab (Figure 1A, right).
The resulting membrane-bound APP
C-terminal fragment (CTFb) is then cut
by g-secretase (a complex of presenilin
and other proteins), thus creating the
C terminus of Ab and causing the libera-
tion and subsequent secretion of the Ab
peptide from the neuron. Accumulation
of Ab in the extracellular milieu of the brain
ultimately leads to the formation of amy-vier Inc.loid plaques and other downstream path-
ophysiological changes in AD. In an
alternative, nonamyloidogenic pathway,
a third enzyme called a-secretase cleaves
APP within the Ab domain, thus preclud-
ing Ab generation (Figure 1A, left). In a
process called ectodomain shedding,
cleavage by a-secretase causes the
secretion of an APP extracellular frag-
ment, sAPPa, which has been reported
to exhibit neuroprotective, neurotrophic,
and neurogenic properties (Caille´ et al.,
2004; Mattson et al., 1993; Ring et al.,
2007). Several enzymes in the ‘‘a dis-
integrin and metalloprotease’’ (ADAM)
family, including ADAM9, ADAM10, and
ADAM17, have a-secretase activity
in vitro, although recent studies have
demonstrated that ADAM10 is the major
a-secretase that catalyzes APP ectodo-
main shedding in the brain (Kuhn et al.,
2010). BACE1 competes with ADAM10
for cleavage of APP substrate, such
that increased BACE1 activity causes
decreased a-secretase processing of
APP and vice versa. Importantly, the
same principle applies for ADAM10,
namely that increased ADAM10 activity
leads to a reduction of b-secretase cleav-
age of APP and Ab generation (Postina
et al., 2004). This observation has two
critical implications: (1) therapeutic strate-
gies that increase ADAM10 activity
should prove efficacious in lowering
cerebral Ab levels for AD, and (2)
decreased ADAM10 activity would be ex-
pected to increase Ab production and AD
pathogenesis.
Previous studies have demonstrated
that ADAM10 function is essential for
neurogenesis and development of the
Figure 1. The Role of ADAM10 Prodomain Mutations in LOAD
(A) In the proamyloidogenic pathway (right side), BACE1 cleavage of APP generates the N terminus of Ab, thus creating the secreted sAPPb ectodomain and
membrane-bound APP CTFb fragments. Next, g-secretase cuts CTFb to produce the C terminus of Ab and the APP intracellular domain (AICD). Ab is then
secreted from the neuron, where it self-aggregates into extracellular amyloid plaques and causes neurodegeneration. In contrast, the antiamyloidogenic pathway
(left side) involves cleavage of APP by ADAM10, leading to the generation ofmembrane-boundAPPCTFa and the secreted sAPPa ectodomain, the latter of which
has neurogenic and neurotrophic properties. g-secretase then cuts CTFa to produce the nonamyloidogenic p3 fragment and the AICD. ADAM10 and BACE1
compete with each other to cut APP, such that changes in the amount of ADAM10 cleavage result in opposite effects on BACE1 processing of APP and vice versa.
(B) ADAM10 is a 748 amino acid type I membrane protein. Upon transit through the trans-Golgi network, the prodomain of ADAM10 is removed by furin or PC7.
The mature enzyme is then trafficked to the plasma membrane, where it performs ectodomain shedding of diverse membrane protein substrates. The asterisks
denote the positions of the two prodomain mutations that cause LOAD; the position of the dominant-negative artificial mutation in the protease domain is also
indicated. The following abbreviation is used: Dis & Cys: disintegrin and cysteine domain.
(C) During synthesis of the enzyme, the wild-type (WT) ADAM10 prodomain serves as an intramolecular chaperone that facilitates correct protein folding of
ADAM10 (left side). After prodomain removal and degradation, mature ADAM10 exhibits full a-secretase activity and performs antiamyloidogenic processing
of APP. In contrast, the mutant (MT) ADAM10 prodomain has impaired intramolecular chaperone function, which results in improper ADAM10 protein folding
and reduced a-secretase activity, thus leading to increased proamyloidogenic cleavage of APP by BACE1 (right side).
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Previewsembryonic brain. Constitutive and con-
ditional Adam10-knockout mice both
exhibit embryonic lethality at early stages
(Hartmann et al., 2002; Jorissen et al.,
2010), most likely as a result of deficient
ADAM10 processing of Notch and its
ligands. ADAM10 is a type I membrane
protein synthesized as an inactive proen-
zyme and has an N-terminal prodomain
that is removed by furin or proprotein con-
vertase 7 (PC7) in the trans-Golgi networkin order for the protease to become
active (Figure 1B). Mature ADAM10 re-
sides on the cell surface, where it per-
forms ectodomain shedding of diverse
membrane protein substrates, including
APP. Although a major function of the
ADAM10 prodomain is to maintain the
enzyme in an inactive state during synthe-
sis and maturation, the prodomain also
functions as an intramolecular chaperone
that assists in the correct folding of theNeuron 80enzyme’s various domains. The impor-
tance of prodomain chaperone function
is underscored by the observation
that expression of a prodomain-deleted
ADAM10 construct results in a proteolyti-
cally inactive enzyme, whereas coexpres-
sion in trans of the prodomain with
prodomain-deleted ADAM10 rescues
enzyme activity (Anders et al., 2001).
Given the role of ADAM10 as the major
APP a-secretase in the brain, Rudy Tanzi, October 16, 2013 ª2013 Elsevier Inc. 251
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Hospital and Harvard University assessed
the candidacy of ADAM10 as a LOAD
susceptibility gene. In a previous study,
the group genotyped 30 SNPs that
spanned ADAM10 and then performed
targeted resequencing of the gene. This
investigation identified two rare highly
penetrant nonsynonymous mutations
(Q170H and R181G) associated with
LOAD in the prodomain of ADAM10 (Kim
et al., 2009). These mutations occurred
in 11 of 16 affected individuals from seven
LOAD-affected families. In cell-culture
experiments, ADAM10 with either the
Q170H or the R181G prodomain mutation
exhibited a-secretase activity that was
reduced by greater than 70%. In addition,
in cells coexpressing the prodomain
mutants with APP, Ab production was
increased 1.5- to 3.5-fold. These results
indicate that ADAM10 is indeed a LOAD
susceptibility gene and suggest the
intriguing possibility that the ADAM10
prodomain mutations reduce proteolytic
activity, even though they are located far
from the active site of the enzyme.
In their article in this issue of Neuron,
the Tanzi group tested the role of the
ADAM10 prodomain mutations in AD
pathogenesis by generating transgenic
mouse lines that express ADAM10
harboring the Q170H or R181Gmutations
in the brain (Suh et al., 2013). They also
made control mouse lines expressing an
artificial dominant-negative (DN) muta-
tion, E384A, or wild-type (WT) ADAM10.
Multiple lines of each transgenic
construct were created, and expression
levels across the various transgenes
were matched. In addition, the team
crossed the different ADAM10 transgenic
lines with the well-characterized APP
transgenic mouse, Tg2576, to determine
the effects of the ADAM10 prodomain
mutations on Ab generation and amyloid
deposition in the brain. They found that
compared to control transgenic mice ex-
pressing WT ADAM10, transgenic mice
expressing ADAM10 with the Q170H
or R181G mutation exhibited reduced
a-secretase cleavage of both endoge-
nous mouse and transgenic human APP.
In contrast, b-secretase processing of
APP was concomitantly increased in
ADAM10 prodomain mutant transgenic
mice compared to in ADAM10-WT mice.
ADAM10-DN transgenic mice exhibited252 Neuron 80, October 16, 2013 ª2013 Elseeven greater decreases and increases of
a-secretase and b-secretase processing
of APP, respectively, than did transgenic
mice expressing either ADAM10-Q170H
or ADAM10-R181G, indicating that the
prodomain mutations attenuated, but did
not eliminate, a-secretase activity.
Next, the team investigated whether
expression of the LOAD ADAM10 prodo-
main mutations could cause elevated
cerebral amyloid deposition. For these
experiments, they crossed the ADAM10-
Q170H transgenic line, which had the
highest APP-CTFb level, with Tg2576
mice and aged the bigenic mice to 3, 12,
and 20 months. Importantly, both endog-
enous soluble and Tg2576 transgenic sol-
uble and insoluble Ab40 and Ab42 levels
were dramatically higher in the brains of
ADAM10-Q170H/Tg2576 bigenic mice
than in those of the ADAM10-WT/
Tg2576 mice, especially by 12 months of
age. At 20 months of age, both amyloid
plaque count and covered area were
significantly increased in the brains of
ADAM10-Q170H/Tg2576 mice relative to
ADAM10-WT/Tg2576 mice. Interestingly,
20 month-old ADAM10-WT/Tg2576 mice
were nearly devoid of amyloid plaques,
whereas age-matched ADAM10-DN/
Tg2576 mice displayed an enormous
plaque burden that was much greater
than that in Tg2576 monogenic mice.
These latter observations provide proof
of concept that increased a-secretase
activity should be an efficacious thera-
peutic strategy for lowering cerebral Ab
accumulation in AD. In addition, aged
ADAM10-Q170H/Tg2576 mice exhibited
greater levels of microgliosis and astro-
gliosis than did ADAM10-WT/Tg2576
bigenic mice. Taken together, these
results demonstrate that the ADAM10
prodomain mutations promote cerebral
amyloid pathology via attenuated a-sec-
retase processing of APP, thus providing
a mechanism for the genetic association
between LOAD and the ADAM10 Q170H
and R181G mutations.
Because previous studies suggested
that sAPPa and ADAM10 play roles in
neurogenesis, Tanzi and colleagues next
investigated whether the ADAM10 prodo-
main mutations affect neurogenesis in the
adult hippocampus. Interestingly, they
found that proliferation of dentate gyrus
neural precursor cells (NPCs) was signifi-
cantly greater in 4-month-old ADAM10-vier Inc.WT transgenicmice than in nontransgenic
mice. In contrast, NPC proliferation in
ADAM10-Q170H, ADAM10-R181G, and
ADAM10-DN mice was similar to that
observed in nontransgenic mice. Impor-
tantly, the dentate gyrus in ADAM10-WT
transgenic mice also displayed 50%
more BrdU:NeuN double-positive neu-
rons than did the dentate gyrus in non-
transgenic mice, whereas the dentate
gyrus in ADAM10-Q170H mice exhibited
a smaller neuronal increase. In addition,
both the total number and the number
with projecting apical dendrites of dou-
blecortin (DCX)-positive immature neu-
rons were significantly higher in the
ADAM10-WT dentate gyrus than in the
nontransgenic dentate gyrus. In contrast,
the number of DCX-positive neurons was
lower in the ADAM10-DN dentate gyrus
than in the nontransgenic dentate gyrus,
whereas the ADAM10-Q170H dentate
gyrus had intermediate values between
the WT and DN DCX-positive neuron
numbers. Together, the results of these
experiments indicate that ADAM10 regu-
lates adult neurogenesis and that the
LOAD prodomain mutations impair the
neurogenic function of ADAM10.
Finally, Tanzi and colleagues endeav-
ored to elucidate the mechanism by
which the prodomain mutations had
attenuated ADAM10 activity. Extensive
cell biological analyses, including subcel-
lular fractionation and surface bio-
tinylation experiments, indicated that the
prodomain mutations did not alter intra-
cellular trafficking of ADAM10 to the
plasma membrane or the synapse, thus
eliminating the possibility that mutant
ADAM10 was unable to reach its appro-
priate cellular destination to cleave APP.
Given that the prodomain of ADAM prote-
ases had previously been shown to
possess a chaperone function that assists
proper protein folding during synthesis of
the enzyme, the group next investigated
whether the activity of inactive prodo-
main-deleted ADAM10 (ADAM10Dpro)
could be rescued by coexpression with
WT or mutant prodomains in trans.
Indeed, coexpression of WT prodomain
efficiently restored the a-secretase activ-
ity of ADAM10Dpro, whereas Q170H or
R181G mutant prodomains failed to do
so. From these results, the authors
concluded that the ADAM10 LOAD
mutations Q170H and R181G impair the
Neuron
Previewsintramolecular chaperone protein-folding
function of the ADAM10 prodomain and
thus result in a misfolded enzyme with
attenuated a-secretase activity.
The current Neuron article of Tanzi and
colleagues is important for several rea-
sons. First, it presents the first definitive
evidence that reduction of a-secretase
activity can cause AD. This hypothesis
has been suggested by past cellular and
animal model studies, but it has never
before been demonstrated in humans
with AD. The study also supports the
inverse of this hypothesis, namely that
therapeutic strategies for increasing
a-secretase activity via ADAM10 upregu-
lation are predicted to be efficacious for
AD. Further, the team showed that
ADAM10 upregulation may prove effec-
tive as an AD therapy through two distinct
mechanisms that act in parallel: (1)
increased a-secretase processing that
competes with b-secretase cleavage of
APP, resulting in reduced Ab generation,
and (2) an increased sAPPa level that
leads to elevated adult neurogenesis in
the hippocampus.
As a therapeutic strategy, upregulation
of ADAM10 activity may prove chal-
lenging. In general, it is more feasible
to develop small-molecule protease in-
hibitors than activators. However, in
principle it may be possible to use
gene-therapy approaches to increase
ADAM10 expression in neurons of the
brain, perhaps in a controllable fashion,
to favor the nonamyloidogenic pathway
of APP processing. Small-molecule acti-
vators to upregulate the expression of
the endogenous ADAM10 may also be
hypothetically possible, although a clear
strategy for this approach is not pres-ently obvious, and challenges concerning
the specificity and control of ADAM10
activation are likely. In addition, the re-
sults of Tanzi and colleagues suggest
a potential therapeutic approach to
increasing adult neurogenesis in AD by
raising sAPPa levels via gene therapy
or direct infusion of sAPPa into the
hippocampus.
Finally, the current study strengthens
the causal link between abnormal Ab
metabolism and LOAD. The hypothesis
that LOAD is caused by cerebral Ab accu-
mulation has been controversial, in part
because rare highly penetrant LOAD
mutations that affect Ab metabolism
have not been found, unlike the case for
EO-FAD. Now, the rare highly penetrant
LOAD mutations in the ADAM10 prodo-
main strongly support the conclusion
that there is no qualitative difference
between EO-FAD and LOAD and that
they share a similar disease mechanism
involving early cerebral Ab accumulation
but that they quantitatively differ in onset
and severity depending on the rate of Ab
accumulation. In other words, EO-FAD
and LOAD are the same disease but
reside in different regions along a patho-
genic continuum. As such, the work of
Tanzi and colleagues represents an
important paradigm shift in the field and
further supports the amyloid cascade
hypothesis of AD.REFERENCES
Anders, A., Gilbert, S., Garten, W., Postina, R., and
Fahrenholz, F. (2001). FASEB J. 15, 1837–1839.
Caille´, I., Allinquant, B., Dupont, E., Bouillot, C.,
Langer, A., Mu¨ller, U., and Prochiantz, A. (2004).
Development 131, 2173–2181.Neuron 80De Strooper, B., Vassar, R., and Golde, T. (2010).
Nat. Rev. Neurol. 6, 99–107.
Hardy, J., and Selkoe, D.J. (2002). Science 297,
353–356.
Hartmann, D., de Strooper, B., Serneels, L., Craes-
saerts, K., Herreman, A., Annaert, W., Umans, L.,
Lu¨bke, T., Lena Illert, A., von Figura, K., and Saftig,
P. (2002). Hum. Mol. Genet. 11, 2615–2624.
Holtzman, D.M., Herz, J., and Bu, G. (2012). Cold
Spring Harb. Perspect. Med. 2, a006312.
Jonsson, T., Atwal, J.K., Steinberg, S., Snaedal, J.,
Jonsson, P.V., Bjornsson, S., Stefansson, H.,
Sulem, P., Gudbjartsson, D., Maloney, J., et al.
(2012). Nature 488, 96–99.
Jorissen, E., Prox, J., Bernreuther, C., Weber, S.,
Schwanbeck, R., Serneels, L., Snellinx, A., Craes-
saerts, K., Thathiah, A., Tesseur, I., et al. (2010).
J. Neurosci. 30, 4833–4844.
Kim, M., Suh, J., Romano, D., Truong, M.H., Mullin,
K., Hooli, B., Norton, D., Tesco, G., Elliott, K., Wag-
ner, S.L., et al. (2009). Hum. Mol. Genet. 18, 3987–
3996.
Kuhn, P.H., Wang, H., Dislich, B., Colombo, A.,
Zeitschel, U., Ellwart, J.W., Kremmer, E., Rossner,
S., and Lichtenthaler, S.F. (2010). EMBO J. 29,
3020–3032.
Mattson, M.P., Cheng, B., Culwell, A.R., Esch,
F.S., Lieberburg, I., and Rydel, R.E. (1993). Neuron
10, 243–254.
Postina, R., Schroeder, A., Dewachter, I., Bohl, J.,
Schmitt, U., Kojro, E., Prinzen, C., Endres, K.,
Hiemke, C., Blessing, M., et al. (2004). J. Clin.
Invest. 113, 1456–1464.
Ring, S., Weyer, S.W., Kilian, S.B., Waldron, E.,
Pietrzik, C.U., Filippov, M.A., Herms, J., Buchholz,
C., Eckman, C.B., Korte, M., et al. (2007).
J. Neurosci. 27, 7817–7826.
Suh, J., Choi, S.H., Romano, D.M., Gannon, M.A.,
Lesinski, A.N., Kim, D.Y., and Tanzi, R.E. (2013).
Neuron 80, this issue, 385–401.
Tanzi, R.E. (2012). Cold Spring Harb. Perspect.
Med. 2, a006296., October 16, 2013 ª2013 Elsevier Inc. 253
